These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 19629072)

  • 21. Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer.
    Bezerra LS; Santos-Veloso MAO; Bezerra Junior NDS; Fonseca LCD; Sales WLA
    Rev Bras Ginecol Obstet; 2018 Dec; 40(12):794-799. PubMed ID: 30536272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
    Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
    JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
    Zembutsu H; Sasa M; Kiyotani K; Mushiroda T; Nakamura Y
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):185-93. PubMed ID: 21342038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
    Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
    Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
    Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
    Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.
    Lammers LA; Mathijssen RH; van Gelder T; Bijl MJ; de Graan AJ; Seynaeve C; van Fessem MA; Berns EM; Vulto AG; van Schaik RH
    Br J Cancer; 2010 Sep; 103(6):765-71. PubMed ID: 20700120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
    Singh MS; Francis PA; Michael M
    Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
    Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
    Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
    Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
    J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
    Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
    Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.
    de Vries Schultink AHM; Huitema ADR; Beijnen JH
    Breast; 2018 Dec; 42():38-40. PubMed ID: 30153552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy.
    Lyon E; Gastier Foster J; Palomaki GE; Pratt VM; Reynolds K; Sábato MF; Scott SA; Vitazka P;
    Genet Med; 2012 Dec; 14(12):990-1000. PubMed ID: 22955113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
    de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
    J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.
    Hertz DL; Kidwell KM; Hilsenbeck SG; Oesterreich S; Osborne CK; Philips S; Chenault C; Hartmaier RJ; Skaar TC; Sikora MJ; Rae JM
    Breast Cancer Res Treat; 2017 Nov; 166(1):277-287. PubMed ID: 28730340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
    Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
    Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
    Stearns V; Rae JM
    Expert Rev Mol Med; 2008 Nov; 10():e34. PubMed ID: 19019258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
    Province MA; Goetz MP; Brauch H; Flockhart DA; Hebert JM; Whaley R; Suman VJ; Schroth W; Winter S; Zembutsu H; Mushiroda T; Newman WG; Lee MT; Ambrosone CB; Beckmann MW; Choi JY; Dieudonné AS; Fasching PA; Ferraldeschi R; Gong L; Haschke-Becher E; Howell A; Jordan LB; Hamann U; Kiyotani K; Krippl P; Lambrechts D; Latif A; Langsenlehner U; Lorizio W; Neven P; Nguyen AT; Park BW; Purdie CA; Quinlan P; Renner W; Schmidt M; Schwab M; Shin JG; Stingl JC; Wegman P; Wingren S; Wu AH; Ziv E; Zirpoli G; Thompson AM; Jordan VC; Nakamura Y; Altman RB; Ames MM; Weinshilboum RM; Eichelbaum M; Ingle JN; Klein TE;
    Clin Pharmacol Ther; 2014 Feb; 95(2):216-27. PubMed ID: 24060820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy.
    Thota K; Prasad K; Basaveswara Rao MV
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):343-350. PubMed ID: 29479969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.
    Puszkiel A; Arellano C; Vachoux C; Evrard A; Le Morvan V; Boyer JC; Robert J; Delmas C; Dalenc F; Debled M; Venat-Bouvet L; Jacot W; Suc E; Sillet-Bach I; Filleron T; Roché H; Chatelut E; White-Koning M; Thomas F
    Clin Pharmacol Ther; 2019 Sep; 106(3):585-595. PubMed ID: 30786012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.
    Skaar TC; Desta Z
    Clin Pharmacol Ther; 2018 May; 103(5):755-757. PubMed ID: 29473149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.